시장보고서
상품코드
1411406

세계의 게놈 편집 시장 : 기술 유통에 초점을 맞춘(게놈 편집 기술 유형별, 치료법 유형별, 게놈 편집 접근법별, 유전자 전달 방법별, 주요 지역별) : 산업 동향 및 예측(2023-2035년)

Genome Editing Market: Focus on Technology-Distribution by Type of Gene Editing Technique, Type of Therapy, Gene Editing Approach, Type of Gene Delivery Method, Key Geographical Regions & Distribution: Industry Trends & Global Forecasts, 2023-2035

발행일: | 리서치사: Roots Analysis | 페이지 정보: 영문 270 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 게놈 편집 시장 규모는 2023년 35억 달러로 평가되었고, 예측 기간(2023-2035년) 동안 12.6%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.

게놈 편집(유전자 교정)은 생물의 유전체 내 단일 유전자(또는 유전자 서열)를 변형(삽입, 삭제, 교체)하는 과정입니다. 최근 유전체 내 특정 부위를 편집할 필요성이 증가하면서 게놈 편집 기업들은 ZFN(징크 핑거 뉴클레아제), TALEN(조직 지방 유사 이펙터 뉴클레아제), 최근에는 CRISPR(cRNA 기반 기술) 등 다양한 유전체 편집 툴을 개발하고 있습니다. 등. 이러한 게놈 편집 도구는 겸상적혈구증(SCD), 파킨슨병(PDD), 난청(HELP), 말초동맥질환(PAD), 척수성 근위축증(SMA), 자가면역질환(AML) 등 유전자 이상으로 인한 임상적 증상을 치료하기 위한 교정 전략으로 널리 활용되고 있습니다. 표적 게놈 편집 치료제를 개발하기 위한 노력이 계속되고 있는 가운데, 2023년 현재 300개 이상의 유전자치료제 후보물질이 임상시험을 진행 중입니다. 주목할 만한 점은 예방 치료도 게놈 편집 응용 시장에서 주목받고 있는 분야라는 점입니다. 그러나 게놈 편집 의약품의 개발에는 유전자 연구 분야에 많은 투자가 필요하다는 점을 명심해야 합니다. 이러한 의약품을 효율적이고 정확하며 안전하게 전달하기 위해 제약회사는 유전체 편집 기업이 개발한 새로운 유전체 편집 기술에 의존하고 있으며, 이는 결국 필요한 유전자 조작을 실현하여 의약품 개발자가 임상 결과를 개선하는 데 도움을 줄 수 있습니다. 유망한 임상시험 결과와 의약품 승인 가속화로 인해 게놈 편집 시장은 향후 몇 년동안 크게 성장할 것으로 예상됩니다.

세계 게놈 편집(Genome Editing) 시장에 대해 분석했으며, 치료 개요와 시장의 기본 구조 및 최신 상황, 주요 시장 성장 촉진요인 및 억제요인, 전체적인 시장 규모 동향 전망, 지역별(3개 지역)-부문별 상세 동향, 최근의 주요 사업제휴-자본거래 동향(투자, M&A 등), 특허 등록 특허 등록 현황, 현재 경쟁 구도, 주요 기업 프로파일 등을 조사하였습니다.

주요 시장 진출기업

  • Arcturus Therapeutics
  • Avectas
  • Beam Therapeutics
  • Bio-Sourcing
  • Caribou Biosciences
  • Century Therapeutics
  • CRISPR Therapeutics
  • EdiGene
  • Editas Medicine
  • Flash Therapeutics
  • Fortgen
  • G FLAS Life Sciences
  • Graphite Bio
  • Intellia Therapeutics
  • Ntrans Technologies
  • OXGENE
  • Prime Medicine
  • Revvity(구 Horizon Discovery)
  • TargetGene Biotechnologies
  • Vor Biopharma
  • ZeClinics

목차

제1장 서론

제2장 조사 방법

제3장 경제 및 기타 프로젝트 특유 고려사항

제4장 주요 요약

제5장 서론

  • 게놈 편집의 개요
  • 게놈 편집 기술의 용도
  • 기타 신기술
  • 결론

제6장 기술 상황

  • 게놈 편집 : 기술 상황
  • 게놈 편집 : 기술 개발자 상황

제7장 기술 경쟁력 분석

  • 전제조건/주요 파라미터
  • 조사 방법
  • 기술 경쟁력 분석

제8장 기업 개요

  • Arcturus Therapeutics
  • Beam Therapeutics
  • Caribou Biosciences
  • Century Therapeutics
  • CRISPR Therapeutics
  • Editas Medicine
  • Graphite Bio
  • Intellia Therapeutics
  • Prime Medicine
  • Vor Biopharma
  • 기타 주요 기업

제9장 파트너십과 협업

  • 파트너십 모델
  • 게놈 편집 기술 : 파트너십과 협업

제10장 특허 분석

  • 분석 범위와 방법
  • 게놈 편집 도메인 : 특허 해석
  • 게놈 편집 도메인 : 특허 벤치마킹 분석
  • 특허 평가액 분석

제11장 자금조달과 투자 분석

  • 자금 유형
  • 게놈 편집 도메인 : 자금조달과 투자 분석

제12장 시장에 대한 영향 분석 : 촉진요인, 억제요인, 기회, 과제

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 시장이 해결해야 할 과제
  • 결론

제13장 게놈 편집 기술 시장

  • 전제조건과 조사 방법
  • 게놈 편집 기술 시장 : 예측(2023-2035년)
  • 주요 시장 구분
  • 다이나믹 대시보드

제14장 게놈 편집 기술 시장 : 게놈 편집 기술 유형별

  • 주요 전제조건과 조사 방법
  • CRISPR-Cas 시스템 : 예측(2023-2035년)
  • TALEN : 예측(2023-2035년)
  • . Meganucleases : 예측(2023-2035년)
  • ZFN : 예측(2023-2035년)
  • 기타 방법 : 예측(2023-2035년)
  • 데이터 계측

제15장 게놈 편집 기술 시장 : 치료 유형별

  • 주요 전제조건과 조사 방법
  • 세포 치료 : 예측(2023-2035년)
  • 유전자 치료 : 예측(2023-2035년)
  • 기타 치료법 : 예측(2023-2035년)
  • 데이터 계측

제16장 게놈 편집 기술 시장 : 게놈 편집 접근별

  • 주요 전제조건과 조사 방법
  • Gene Knock-Out 접근 : 예측(2023-2035년)
  • Gene Knock-In 접근 : 예측(2023-2035년)
  • 데이터 계측

제17장 게놈 편집 기술 시장 : 유전자 전달 방법별

  • 주요 전제조건과 조사 방법
  • Ex-Vivo(생체외) 전달 방법 : 예측(2023-2035년)
  • In-Vivo(생체내) 전달 방법 : 예측(2023-2035년)
  • 데이터 계측

제18장 게놈 편집 기술 시장 : 유전자 도입 모달리티별

  • 주요 전제조건과 조사 방법
  • 바이러스 벡터 : 예측(2023-2035년)
  • 비바이러스 벡터 : 예측(2023-2035년)
  • 데이터 계측

제19장 게놈 편집 기술 시장 : 활용 영역별

  • 주요 전제조건과 조사 방법
  • Drug Discovery & Development : 예측(2023-2035년)
  • 진단 : 예측(2023-2035년)
  • 데이터 계측

제20장 게놈 편집 기술 시장 : 최종사용자 유형별

  • 주요 전제조건과 조사 방법
  • 제약 기업 및 바이오테크놀러지 기업 : 예측(2023-2035년)
  • 학술기관 및 연구기관 : 예측(2023-2035년)
  • 데이터 계측

제21장 게놈 편집 기술 시장 : 주요 지역별

  • 주요 전제조건과 조사 방법
  • 북미 : 예측(2023-2035년)
  • 유럽 : 예측(2023-2035년)
  • 아시아태평양 : 예측(2023-2035년)
  • 데이터 계측

제22장 게놈 편집 기술 시장 : 사용되는 결제 수단 유형별

  • 주요 전제조건과 조사 방법
  • 마일스톤 지불 : 예측(2023-2035년)
  • 선불 : 예측(2023-2035년)
  • 데이터 계측

제23장 게놈 편집 기술 시장 : 주요 시장 진출기업

  • 업계를 리드하는 기업

제24장 결론

제25장 주요 인사이트

제26장 부록 1 : 표 형식 데이터

제27장 부록 2 : 기업 및 조직 리스트

LSH 24.01.30

The genome editing marketis valued at USD 3.5 billion in 2023 growing at a CAGR of 12.6% during the forecast period 2023-2035.

Gene editing or gene replacement is the process of modifying (inserting, deleting or replacing) a single gene (or a sequence of genes) in the genome of a living organism. In recent years, the need to edit at a specific site within the genome has increased, there has been a surge in the development of different types of genome editing tools by gene-editing companies. These include ZFNs (zinc finger nucleases), TALENs (tissue-aliphatic-like-effector nucleases) and, most recently, CRISPR (cRNA-based technology). These gene-editing tools have been widely used as a corrective strategy to treat clinical conditions resulting from genetic abnormalities, including Sickle cell disease (SCD), Parkinson's disease (PDD), hearing loss (HELP), peripheral artery disease (PAD), spinal muscular atrophies (SMA), autoimmune diseases (AML) and other types of genetic disorders. In the midst of the current efforts to create targeted gene-editing therapies, there are more than 300 candidates for gene therapy in clinical trials as of 2023. It is worth mentioning, prophylaxis treatment is another segment that has attracted a lot of attention in the market of gene editing applications. However, it is important to note that the development of a gene edited drug product involves a significant investment in the development of drugs in the field of gene research. In order to deliver these drugs efficiently, precisely and safely, the pharma companies are relying on new genome editing technologies developed by the genome editing companies, which in turn will help the drug developers in improving the clinical outcome by achieving the required genetic manipulation. With encouraging clinical trial results and accelerated drug approval, the market for genome editing is expected to experience significant growth over the next few years.

Key Market Segments

Type of Gene Editing Technique

  • CRISPR-Cas System
  • TALENs
  • Meganucleases
  • ZFNs
  • Other Techniques

Type of Therapy

  • Cell Therapies
  • Gene Therapies
  • Other Therapies
  • Gene Editing Approach
  • Gene Knock-Out Approaches
  • Gene Knock- In Approaches
  • Gene Delivery Method
  • Ex-Vivo Delivery Methods
  • In-Vivo Delivery Methods
  • Gene Delivery Modality
  • Viral Vectors
  • Non-Viral Vectors
  • Application Area
  • Drug Discovery and Development
  • Diagnostics

Type of End User

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific
  • Payment Method Employed
  • Upfront Payments
  • Milestone Payments

Research Coverage:

The report studies the genome editing market based on type of gene editing technique, type of therapy, gene editing approach, gene delivery method, gene delivery modality, application area, type of end user, key geographical regions and payment method employed.

The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.

The report forecasts the revenue of market segments with respect to three major regions

The report includes a brief introduction to genome editing, including the evolution of the domain over the years, a list of the different genome editing technologies, and an overview of how genome editing is being used in different industries such as biotechnology, pharma and agriculture. It also highlights the various cutting-edge genome editing technologies.

Comprehensive analysis of the current technology landscape for genome editing domain considering parameters such as type of gene editing technique (CRISPR-Cas system, meganucleases, TALENs, ZFNs and other techniques), gene editing approach, type of gene delivery method, type of gene delivery modality, highest phase of drug development supported, therapeutic area and application. In addition, the chapter features information on various technology developers, along with analysis based on multiple parameters, establishment year, company size, headquarters and operational model

Create detailed profiles of leading genome editing companies, including establishment year, employees, HQ location, key executives, technology portfolios, recent developments, and future outlook.

Detailed company competitiveness evaluation of medical aesthetics company, considering developer strength and technology strength in terms of type of gene editing technique, gene editing approach, in-silico (CADD) analysis, type of gene delivery method, type of gene delivery modality, highest phase of development supported and application area.

Examine partnerships (licensing agreements, research and development agreements, technology integration agreements, etc.) in the genome editing market from 2018-2023. Analyze recent investments (grants, funding rounds) and initiatives by market stakeholders.

Review patents related to genome editing from 2018-2023, highlighting types, publication years, locations, CPC symbols, focus areas, applicant types, and leading players.

The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the genome editing market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies

  • Arcturus Therapeutics
  • Avectas
  • Beam Therapeutics
  • Bio-Sourcing
  • Caribou Biosciences
  • Century Therapeutics
  • CRISPR Therapeutics
  • EdiGene
  • Editas Medicine
  • Flash Therapeutics
  • Fortgen
  • G+FLAS Life Sciences
  • Graphite Bio
  • Intellia Therapeutics
  • Ntrans Technologies

    OXGENE

  • Prime Medicine
  • Revvity (formerly known as Horizon Discovery)
  • TargetGene Biotechnologies
  • Vor Biopharma
  • ZeClinics

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Key Market Insights
  • 1.3. Scope of the Report
  • 1.4. Research Methodology
  • 1.5. Frequently Asked Questions
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact / Related Factors
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Forecasted Estimates
    • 3.2.2. Currency Coverage
      • 3.2.2.1. Overview of Major Currencies Affecting the Market
      • 3.2.2.2. Impact of Currency Fluctuations on the Industry
    • 3.2.3. Foreign Exchange Impact
      • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past

Recessions and Lessons Learnt

      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Introduction to Genome Editing
    • 5.2.1. Evolution of Genome Editing
    • 5.2.2. Genome Editing Technologies
      • 5.2.2.1. CRISPR - Cas System
      • 5.2.2.2. Transcription Activator-Like Effector Nucleases (TALENs)
      • 5.2.2.3. Zinc Finger Nucleases (ZFNs)
      • 5.2.2.4. Meganucleases / Homing Endonucleases
  • 5.3. Applications of Genome Editing Technologies
  • 5.4. Other Emerging Technologies
  • 5.5. Concluding Remarks

6. TECHNOLOGY LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Genome Editing: Technology Landscape
    • 6.2.1. Analysis by Type of Gene Editing Technique
    • 6.2.2. Analysis by Gene Editing Approach
    • 6.2.3. Analysis by Type of Gene Delivery Method
    • 6.2.4. Analysis by Type of Gene Delivery Modality
    • 6.2.5. Analysis by Highest Phase of Drug Development Supported
    • 6.2.6. Analysis by Therapeutic Area
    • 6.2.7. Analysis by Application Area
  • 6.3. Genome Editing: Technology Developer Landscape
    • 6.3.1. Analysis by Year of Establishment
    • 6.3.2. Analysis by Company Size
    • 6.3.3. Analysis by Location of Headquarters
    • 6.3.4. Analysis by Operational Model
    • 6.3.5. Most Active Players: Distribution by Number of Technologies

7. TECHNOLOGY COMPETITIVENESS ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Assumptions / Key Parameters
  • 7.3. Methodology
  • 7.4. Technology Competitiveness Analysis
    • 7.4.1. Genome Editing Technologies Offered by Players based in North America
    • 7.4.2. Genome Editing Technologies Offered by Players based in Europe
    • 7.4.3. Genome Editing Technologies Offered by Players based in Asia-Pacific, Middle East and North Africa, and Latin America

8. COMPANY PROFILES

  • 8.1. Chapter Overview
  • 8.2. Arcturus Therapeutics
    • 8.2.1. Company Overview
    • 8.2.2. Financial Information
    • 8.2.3. Technology Portfolio
    • 8.2.4. Recent Developments and Future Outlook
  • 8.3. Beam Therapeutics
    • 8.3.1. Company Overview
    • 8.3.2. Financial Information
    • 8.3.3. Technology Portfolio
    • 8.3.4. Recent Developments and Future Outlook
  • 8.4. Caribou Biosciences
    • 8.4.1. Company Overview
    • 8.4.2. Financial Information
    • 8.4.3. Technology Portfolio
    • 8.4.4. Recent Developments and Future Outlook
  • 8.5. Century Therapeutics
    • 8.5.1. Company Overview
    • 8.5.2. Financial Information
    • 8.5.3. Technology Portfolio
    • 8.5.4. Recent Developments and Future Outlook
  • 8.6. CRISPR Therapeutics
    • 8.6.1. Company Overview
    • 8.6.2. Financial Information
    • 8.6.3. Technology Portfolio
    • 8.6.4. Recent Developments and Future Outlook
  • 8.7. Editas Medicine
    • 8.7.1. Company Overview
    • 8.7.2. Financial Information
    • 8.7.3. Technology Portfolio
    • 8.7.4. Recent Developments and Future Outlook
  • 8.8. Graphite Bio
    • 8.8.1. Company Overview
    • 8.8.2. Technology Portfolio
    • 8.8.3. Recent Developments and Future Outlook
  • 8.9. Intellia Therapeutics
    • 8.9.1. Company Overview
    • 8.9.2. Financial Information
    • 8.9.3. Technology Portfolio
    • 8.9.4. Recent Developments and Future Outlook
  • 8.10. Prime Medicine
    • 8.10.1. Company Overview
    • 8.10.2. Technology Portfolio
    • 8.10.3. Recent Developments and Future Outlook
  • 8.11. Vor Biopharma
    • 8.11.1. Company Overview
    • 8.11.2. Technology Portfolio
    • 8.11.3. Recent Developments and Future Outlook
  • 8.12. Other Leading Players
    • 8.12.1. Avectas
    • 8.12.2. Bio-Sourcing
    • 8.12.3. Edigene
    • 8.12.4. Flash Therapeutics
    • 8.12.5. Fortgen
    • 8.12.6. G+FLAS Life Sciences
    • 8.12.7. Ntrans Technologies
    • 8.12.8. OXGENE
    • 8.12.9. Revvity (formerly known as Horizon Discovery)
    • 8.12.10. TargetGene Biotechnologies
    • 8.12.11. ZeClinics

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Genome Editing Technologies: Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Year and Type of Partnership
    • 9.3.4. Analysis by Type of Partner
    • 9.3.5. Analysis by Location of Headquarters of Partner
    • 9.3.6. Most Active Players: Analysis by Number of Partnerships
    • 9.3.7. Analysis by Geography
      • 9.3.7.1. Local and International Agreements
      • 9.3.7.2. Intercontinental and Intracontinental Agreements

10. PATENT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Genome Editing Domain: Patent Analysis
    • 10.3.1. Analysis by Publication Year
    • 10.3.2. Analysis by Type of Patent and Publication Year
    • 10.3.3. Analysis by Geography
    • 10.3.4. Analysis by CPC Symbols
    • 10.3.5. Leading Industry Players: Analysis by Number of Patents
  • 10.4. Genome Editing Domain: Patent Benchmarking Analysis
    • 10.4.1. Analysis by Patent Characteristics
    • 10.4.2. Analysis by Leading Industry Players
  • 10.5. Patent Valuation Analysis

11. FUNDING AND INVESTMENT ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Types of Funding
  • 11.3. Genome Editing Domain: Funding and Investment Analysis
    • 11.3.1. Analysis by Year of Investment
      • 11.3.1.1. Cumulative Year-wise Trend of Funding Instances
      • 11.3.1.2. Cumulative Year-wise Trend of Amount Invested
    • 11.3.2. Analysis by Type of Funding
      • 11.3.2.1. Analysis of Funding Instances
      • 11.3.2.2. Analysis of Amount Invested
    • 11.3.3. Analysis by Year and Type of Funding
    • 11.3.4. Analysis by Geography
    • 11.3.5. Most Active Players: Analysis by Amount Invested and Number of Funding Instances
    • 11.3.6. Leading Investors: Analysis by Number of Funding Instances

12. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 12.1. Chapter Overview
  • 12.2. Market Drivers
  • 12.3. Market Restraints
  • 12.4. Market Opportunities
  • 12.5. Market Challenges
  • 12.6. Conclusion

13. GENOME EDITING TECHNOLOGIES MARKET

  • 13.1. Chapter Overview
  • 13.2. Assumptions and Methodology
  • 13.3. Genome Editing Technologies Market, Forecasted Estimates (2023-2035)
    • 13.3.1. Scenario Analysis
  • 13.4. Key Market Segmentations
  • 13.5. Dynamic Dashboard

14. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF GENE EDITING TECHNIQUE

  • 14.1. Chapter Overview
  • 14.2. Key Assumptions and Methodology
  • 14.3. CRISPR-Cas System: Forecasted Estimates (2023-2035)
  • 14.4. TALENs: Forecasted Estimates (2023-2035)
  • 14.5. Meganucleases: Forecasted Estimates (2023-2035)
  • 14.6. ZFNs: Forecasted Estimates (2023-2035)
  • 14.7. Other Techniques: Forecasted Estimates (2023-2035)
  • 14.8. Data Triangulation
    • 14.8.1. Insights from Primary Research
    • 14.8.2. Insights from Secondary Research
    • 14.8.3. Insights from In-house Repository

15. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF THERAPY

  • 15.1. Chapter Overview
  • 15.2. Key Assumptions and Methodology
  • 15.3. Cell Therapies: Forecasted Estimates (2023-2035)
  • 15.4. Gene Therapies: Forecasted Estimates (2023-2035)
  • 15.5. Other Therapies: Forecasted Estimates (2023-2035)
  • 15.6. Data Triangulation
    • 15.6.1. Insights from Primary Research
    • 15.6.2. Insights from Secondary Research
    • 15.6.3. Insights from In-house Repository

16. GENOME EDITING TECHNOLOGIES MARKET, BY GENE EDITING APPROACH

  • 16.1. Chapter Overview
  • 16.2. Key Assumptions and Methodology
  • 16.3. Gene Knock-Out Approaches: Forecasted Estimates (2023-2035)
  • 16.4. Gene Knock-In Approaches: Forecasted Estimates (2023-2035)
  • 16.5. Data Triangulation
    • 16.5.1. Insights from Primary Research
    • 16.5.2. Insights from Secondary Research
    • 16.5.3. Insights from In-house Repository

17. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY METHOD

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Ex-Vivo Delivery Methods: Forecasted Estimates (2023-2035)
  • 17.4. In-Vivo Delivery Methods: Forecasted Estimates (2023-2035)
  • 17.5. Data Triangulation
    • 17.5.1. Insights from Primary Research
    • 17.5.2. Insights from Secondary Research
    • 17.5.3. Insights from In-house Repository

18. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY MODALITY

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Viral Vectors: Forecasted Estimates (2023-2035)
  • 18.4. Non-Viral Vectors: Forecasted Estimates (2023-2035)
  • 18.5. Data Triangulation
    • 18.5.1. Insights from Primary Research
    • 18.5.2. Insights from Secondary Research
    • 18.5.3. Insights from In-house Repository

19. GENOME EDITING TECHNOLOGIES MARKET, BY APPLICATION AREA

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. Drug Discovery and Development: Forecasted Estimates (2023-2035)
  • 19.4. Diagnostics: Forecasted Estimates (2023-2035)
  • 19.5. Data Triangulation
    • 19.5.1. Insights from Primary Research
    • 19.5.2. Insights from Secondary Research
    • 19.5.3. Insights from In-house Repository

20. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF END USER

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Pharmaceutical and Biotechnology Companies: Forecasted Estimates (2023-2035)
  • 20.4. Academic and Research Institutes: Forecasted Estimates (2023-2035)
  • 20.5. Data Triangulation
    • 20.5.1. Insights from Primary Research
    • 20.5.2. Insights from Secondary Research
    • 20.5.3. Insights from In-house Repository

21. GENOME EDITING TECHNOLOGIES MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions and Methodology
  • 21.3. North America: Forecasted Estimates (2023-2035)
  • 21.4. Europe: Forecasted Estimates (2023-2035)
  • 21.5. Asia-Pacific: Forecasted Estimates (2023-2035)
  • 21.6. Data Triangulation
    • 21.6.1. Insights from Primary Research
    • 21.6.2. Insights from Secondary Research
    • 21.6.3. Insights from In-house Repository

22. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF PAYMENT METHOD EMPLOYED

  • 22.1. Chapter Overview
  • 22.2. Key Assumptions and Methodology
  • 22.3. Milestone Payments: Forecasted Estimates (2023-2035)
  • 22.4. Upfront Payments: Forecasted Estimates (2023-2035)
  • 22.5. Data Triangulation
    • 22.5.1. Insights from Primary Research
    • 22.5.2. Insights from Secondary Research
    • 22.5.3. Insights from In-house Repository

23. GENOME EDITING TECHNOLOGIES MARKET: LEADING INDUSTRY PLAYERS

  • 23.1. Chapter Overview
  • 23.2. Leading Industry Players

24. CONCLUSION

25. EXECUTIVE INSIGHTS

26. APPENDIX 1: TABULATED DATA

27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제